contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-wins-new-clinical-segment-client-in-turkey

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analyst

Frans-Mikael Rostedt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Here are Siltanen’s preview comments as Aiforia reports its H2 results on Friday, March 6.  We expect Aiforia’s revenue growth to have accelerated towards the end of the year, supported by the ramp-up of clinical customer accounts. We estimate the result to have remained loss-making. In the report, our focus will be particularly on revenue growth, the development of the order book, and the updated assessment of the adequacy of the financial position.                   Inderes              Aiforia H2'25 -ennakko: Kääntyvätkö asiakasvoitot kasvuksi? - Inderes    Odotamme liikevaihdon kasvua kliinisten asiakkuuksien tukemana.

This also happened last February, the same amount of 400,000.

…”apparently for some reason moved to a nominee register.” Pardon me, but I cannot believe that shares would accidentally move to a nominee register without the owner’s explicit request, even if switching banks. Everyone can ponder the reasons for themselves.

It’s great when the CEO himself is commenting and shutting down a couple of days of speculation and rumors  This is how it goes on the Inderes forum

Hi, yeah, preview tomorrow and interview on Friday.

Hi, just confirming that I haven’t sold any Aiforia shares, they have apparently for some reason moved to a nominee register. I changed banks regarding 400,000 shares. Best regards, Jukka Tapaninen

@Antti_Siltanen @Antti_Luiro Will there be a preview and/or a CEO interview for Aiforia after the report?

Aiforia Technologies

Memorial Hospitals Group in Turkey has selected Aiforia as its partner for AI-assisted clinical diagnostics in pathology. Memorial Hospitals Group is the largest private hospital group in Turkey, serving 75,000 patients annually in 11 hospitals.

Translation: Original published in Finnish on 12/2/2024 at 4:24 pm EET.
According to a&#xa0;<a href="https://www.inderes.se/releases/memorial-hospitals-group-in-turkey-selects-aiforia-as-the-partner-for-ai-assisted-clinical-diagnostics-in-pathology">press release</a>, Memorial Hospitals Group in Turkey has selected Aiforia as its partner for AI-assisted clinical diagnostics in pathology. Memorial Hospitals Group is the largest private hospital group in Turkey, serving 75,000 patients annually in 11 hospitals. The collaboration will utilize Aiforia&apos;s regulatory-approved clinical AI solutions to analyze biopsies from breast, prostate and lung cancer patients at the Memorial Pathology Center laboratory. 
According to the press release, Memorial Pathology is the first pathology laboratory in Turkey with a fully digital workflow and all biopsy samples are digitalized. This phase is required to implement Aiforia&apos;s image analysis solutions and is often time-consuming, but with a fully digital setting, the customer could start generating revenue for Aiforia as early as the beginning of 2025. We have included new deals in our forecasts and have been waiting for the company to announce them, so this release does not come as a surprise or put immediate pressure on our forecasts. Of course, the announcement supports our forecasts and is another sign that Aiforia&apos;s solution is competitive in the market and that the market development in Europe will continue.

	2023	24e	25e
Revenue	2.4	3.4	5.8
growth-%	49.3 %	41.2 %	71.1 %
EBIT (adj.)	-12.9	-12.1	-11.8
EBIT-% (adj.)	-537.1 %	-358.4 %	-204.4 %
EPS (adj.)	-0.50	-0.42	-0.41
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia wins new clinical segment client in Turkey

Key Estimate Figures2024-10-02

Forum discussions